Please provide your email address to receive an email when new articles are posted on . Older men with higher concentrations of three bone turnover markers have a higher risk for all-cause mortality ...

A phase I study of IPH2101, a novel anti-inhibitory KIR monoclonal antibody, in patients with multiple myeloma. Background: Aminobisphosphonates (aBP) are standard of care for myeloma related bone ...

Odanacatib, Merck's Investigational Cathepsin K Inhibitor, Reduced Markers of Bone Turnover in Women with Breast Cancer and Bone Metastases Results from Studies of Other Investigational Merck Cancer ...

Please provide your email address to receive an email when new articles are posted on . Results showed bone quality was abnormal in ankle arthritis on the affected side. However, bone quality was ...

Patients with advanced solid tumors frequently experience bone metastases, which increase rates of bone turnover. Changes in bone resorption and formation can be monitored by measuring biochemical ...

Youths with type 1 diabetes (T1D) show lower bone accrual than expected for their age, gender, pubertal stage, lean mass accrual, and growth, with greater urinary calcium excretion being associated ...

Bone turnover markers (BTMs) in blood and urine are useful tools in monitoring osteoporosis treatment effects and may be useful for improving patient adherence. In 2011, a Joint Committee on Bone ...

Aging and lifestyle-related metabolic imbalances, such as hyperglycemia, hyperlipidemia, and oxidative-stress, cause the accumulation of advanced glycation end products (AGEs), including pentosidine ...

Treatment and clinical outcome of young (age 40 and younger) patients with advanced non-small cell lung (NSCLC). Background: Between 19 to 44% of patients with lung cancer eventually develop bone ...

A multidisciplinary team of researchers has discovered several genetic markers associated with bone mineral accrual, which could ultimately help identify causes of eventual osteoporosis earlier in ...

A genetic change that affects the transcription factor, FOS, is a hallmark mutation of osteoblastoma (bone tumor), said scientists at the Wellcome Sanger Institute and their collaborators. The results ...